Johannes Oldenburg

Overview

Best Publications

• Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

  Simone Rost;Andreas Fregin;Vytautas Ivaskevicius;Ernst Conzelmann

  1483
  Citations

• Emicizumab Prophylaxis in Hemophilia A with Inhibitors

  Johannes Oldenburg;Johnny N. Mahlangu;Benjamin Kim;Christophe Schmitt

  1016
  Citations

• Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

  Johnny Mahlangu;Johannes Oldenburg;Ido Paz-Priel;Claude Negrier

  663
  Citations

• Haemophilia A: mutation type determines risk of inhibitor formation.

  Rainer Schwaab;H.-H. Brackmann;C. Meyer;J. Seehafer

  430
  Citations

• The Genetic Basis of Resistance to Anticoagulants in Rodents

  Hans-Joachim Pelz;Simone Rost;Mirja Hünerberg;Andreas Fregin

  422
  Citations

• F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

  Samantha C. Gouw;Samantha C. Gouw;H. Marijke van den Berg;Johannes Oldenburg;Jan Astermark

  417
  Citations

• Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.

  Johannes Oldenburg

  379
  Citations

• VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

  Christof Geisen;Matthias Watzka;Katja Sittinger;Michael Steffens

  350
  Citations

• Genetic risk factors for inhibitors to factors VIII and IX.

  J. Oldenburg;A. Pavlova

  349
  Citations

• Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

  Jan Astermark;Johannes Oldenburg;Anna Pavlova;Erik Berntorp

  340
  Citations

• Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

  Samantha C. Gouw;H. Marijke van den Berg;Kathelijn Fischer;Guenter Auerswald

  339
  Citations

• A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

  Guy Young;Ri Liesner;Tiffany Yung-Chin Chang;Robert Francis Sidonio

  333
  Citations

• Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

  Heike Pfeifer;Barbara Wassmann;Anna Pavlova;Lydia Wunderle

  333
  Citations

• Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males.

  Osman El-Maarri;Tim Becker;Judith Junen;Syed Saadi Manzoor

  326
  Citations

• Immune Tolerance for the Treatment of Factor VIII Inhibitors - Twenty Years' ‘Bonn Protocol’

  H. H. Brackmann;J. Oldenburg;R. Schwaab

  320
  Citations

• Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

  Jan Astermark;Johannes Oldenburg;Joyce Carlson;Anna Pavlova

  284
  Citations

• Haemophilia A: from mutation analysis to new therapies

  Jochen Graw;Hans-Hermann Brackmann;Johannes Oldenburg;Reinhard Schneppenheim

  256
  Citations

• HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII.

  J Oldenburg;J K Picard;R Schwaab;H H Brackmann

  255
  Citations

• Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.

  Johannes Oldenburg;Robert Klamroth;Florian Langer;Manuela Albisetti

  249
  Citations

• Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

  Corien L. Eckhardt;Alice S. Van Velzen;Marjolein Peters;Jan Astermark

  241
  Citations